Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome

Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome

BACKGROUND: The International Network for the Study of HIV-associated IRIS (INSHI) recently published criteria for tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) diagnosis. The performance of this definition and clinical manifestations of TB-IRIS were studied. METHODS:...

Full description

Saved in:

Bibliographic Details
Main Authors:	Weerawat Manosuthi, Hong Van Tieu, Wiroj Mankatitham, Aroon Lueangniyomkul, Jintanat Ananworanich, Anchalee Avihingsanon, Umaporn Siangphoe, Sukonsri Klongugkara, Sirirat Likanonsakul, Unchana Thawornwan, Bussakorn Suntisuklappon, Somnuek Sungkanuparph
Other Authors:	Thailand Ministry of Public Health
Format:	Article
Published:	2018
Subjects:	Immunology and Microbiology Medicine
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/27639
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study
by: Weerawat Manosuthi, et al.
Published: (2018)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
by: Weerawat Manosuthi, et al.
Published: (2018)

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study
by: Weerawat Manosuthi, et al.
Published: (2018)

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy
by: Weerawat Manosuthi, et al.
Published: (2018)

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
by: Weerawat Manosuthi, et al.
Published: (2018)

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in hiv-infected patients receiving rifampicin: The n<inf>2</inf>r study
by: Weerawat Manosuthi, et al.
Published: (2018)

Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy
by: Weerawat Manosuthi, et al.
Published: (2018)

Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis
by: Weerawat Manosuthi, et al.
Published: (2018)

Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting
by: Weerawat Manosuthi, et al.
Published: (2018)

Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
by: Weerawat Manosuthi, et al.
Published: (2018)

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin
by: W. Manosuthi, et al.
Published: (2018)

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3
by: Weerawat Manosuthi, et al.
Published: (2018)

Reply to chang et al
by: Weerawat Manosuthi, et al.
Published: (2018)

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: A 144-week prospective study
by: Weerawat Manosuthi, et al.
Published: (2018)

Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/μL
by: Weerawat Manosuthi, et al.
Published: (2018)

Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis [1]
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Thoracic manifestations of paradoxical immune reconstitution inflammatory syndrome during or after antituberculous therapy in HIV-negative patients
by: Prapaporn Pornsuriyasak, et al.
Published: (2018)

Integrated therapy for HIV and tuberculosis
by: Weerawat Manosuthi, et al.
Published: (2018)

Optimal timing of antiretroviral therapy initiation in patients coinfected with HIV and tuberculosis
by: Sasisopin Kiertiburanakul, et al.
Published: (2018)

Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis
by: Weerawat Manosuthi, et al.
Published: (2018)

Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone
by: Sukanya Chimsuntorn, et al.
Published: (2018)

Integrated therapy for HIV and tuberculosis
by: Weerawat Manosuthi, et al.
Published: (2017)

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study
by: Weerawat Manosuthi, et al.
Published: (2018)

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis
by: Weerawat Manosuthi, et al.
Published: (2018)

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
by: Weerawat Manosuthi, et al.
Published: (2018)

HIV-1 drug resistance-associated mutations among antiretroviral-naive thai patients with chronic HIV-1 infection
by: Weerawat Manosuthi, et al.
Published: (2018)

Comparison of thai government manufactured tenofovir (Tenofovir GPO300) with privately manufactured tenofovir (Viread) used along with lamivudine and efavirenz to treat Thai HIV patients
by: Weerawat Manosuthi, et al.
Published: (2018)

Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy
by: Pawinee Wongprasit, et al.
Published: (2018)

Diagnostic value of percutaneous liver biopsy in fever of unkown origin in patients with human immunodeficiency virus infection
by: Surasak Wiboonchutikul, et al.
Published: (2018)

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: A case-control study
by: Weerawat Manosuthi, et al.
Published: (2018)

Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
by: Weerawat Manosuthi, et al.
Published: (2018)

Clinical experience with high success rate of antiretroviral therapy in elderly HIV-infected patients [9]
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Compliance with hepatitis b and hepatitis c virus infection screening among hiv-1 infected patients in a resource-limited setting
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Letter to the editor: Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting [1]
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Reply to Vogenthaler [2]
by: Somnuek Sungkanuparph, et al.
Published: (2018)

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
by: Weerawat Manosuthi, et al.
Published: (2018)